Actively Recruiting
Preference of Life-Sustaining Treatment Among Patients With End Stage Renal Disease
Led by National Taiwan University Hospital · Updated on 2024-10-18
200
Participants Needed
2
Research Sites
105 weeks
Total Duration
On this page
Sponsors
N
National Taiwan University Hospital
Lead Sponsor
N
National Taipei University of Nursing and Health Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
Although patients with kidney disease can rely on dialysis to prolong their lives, the complexity of the disease, the variability of the course of the disease, and the uncertainty of the prognosis often delay the discussion of issues at the end of life, and the deterioration of the condition often makes it impossible for the patient to express clearly or rationally. Treatment thoughts or preferences. Sufficient time is needed to think and discuss issues related to life treatment. Discuss with patients as soon as possible to help draw up end-of-life care plans, help patients realize end-of-life care preferences, assist family members to make complex treatment decisions, and alleviate medical providers' moral distress. Domestic life-sustaining treatment research is mostly signed by DNR for cancer patients and retrospective investigation of medical records, and seldom focuses on kidney disease patients and life-sustaining treatment survey preferences other than DNR content. This study sought to understand patients with kidney disease's preferences for life-sustaining care during disease progression, and to understand whether prognostic perceptions, symptom distress, dementia, and decision conflict affect patients' preferences. Pre-collected convenient sampling is expected to include 200 patients diagnosed with chronic kidney disease stage 5 or end-stage renal disease, including patients who have received regular dialysis. The survey will be conducted with a single questionnaire. There are five questionnaires, including: demographic characteristics, chronic kidney disease prognosis cognition And life-support treatment information questionnaire, short-form recall symptom assessment scale, loss of memory scale and decision-making conflict scale; after the researcher explains, the patient fills in by himself or the researcher fills in after the patient answers. It is expected that the results of the study will help clinical practitioners to understand the changes in the management of medical care for kidney disease patients when the disease worsens and assist in the management of patients' medical care, echoing the importance of advancing medical care planning in this population, for the future development of kidney disease A reference for care guidelines for debilitated patients, thereby improving care quality and satisfaction.
CONDITIONS
Official Title
Preference of Life-Sustaining Treatment Among Patients With End Stage Renal Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 20 years old
- Diagnosed with chronic kidney disease stage V or end-stage renal disease with glomerular filtration rate less than 15ml/min/1.73m2
- Receiving regular blood or peritoneal dialysis treatment
- Have normal cognitive function (able to read and communicate)
- Can communicate in Mandarin or Taiwanese
You will not qualify if you...
- Severe cognitive impairment or visual or hearing impairment preventing answering questions
- Critically ill patients
- Patients with chronic mental illness or related diagnosis records
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
National Taiwan University Hospital
Taipei, Taiwan, 100
Actively Recruiting
2
National Taipei University of Nursing and Health Sciences
Taipei, Taiwan
Completed
Research Team
C
Chan-Shiuan Kuo
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here